ClinicalTrials.gg
Active, not recruitingNCT06472908Updated Sep 3, 2026

Efficacy and Safety of Colchicine After PCI

A Phase 3 interventional study of Colchicine 0.5 mg and Colchicine 0.375 mg in Coronary Heart Disease, Percutaneous Coronary Intervention and Colchicine, sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Active, not recruiting at 36 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
8,862
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 224 studies in Coronary Disease with a site in China — 68 open to participants now, 78 under way, 3 of them phase 3. Coronary Disease · China.

Planned enrollment
6th of 142
8,862 · median 220
Started
2024
with 16 others
Phase 3
9 of 224
2 open now
Primary completion
2027-06
later than 53 of 77 live
Registered
171st of 224
by date

Among the 224 studies in Coronary Disease with a site in China, this one is the 6th largest by planned enrollment of the 142 interventional ones that give a count, is one of 17 that started in 2024, is one of 9 in phase 3, reaches primary completion later than 53 of the 77 other live ones, and was the 171st registered.

Coronary Disease

1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.

Browse Coronary Disease studies →

Open to participants now

68 of the 224 studies in Coronary Disease with a site in China are open now. Recruiting first, the newest first:

63 more — sign in →

All 68 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 224 studies in Coronary Disease with a site in China, or all of them as a file.
02

Study summary

Colchicine (0.5 mg/day) was recommended by the U.S. Food and Drug Administration in 2023 for the anti-inflammatory treatment of coronary heart disease (CHD). However, colchicine is still not approved for CHD treatment in China. There is no large-scale clinical evidence that colchicine can be used to treat Chinese patients with CHD. Considering the low body weight of the East Asian population, it is unclear whether the recommended standard dose (0.5 mg/day) is suitable for Chinese patients. Therefore, we need to further explore the effects of different doses of colchicine on the efficacy and safety of clinical endpoints in the Chinese population with CHD.

This study is a multicenter, prospective, randomized, controlled, double-blind, event-driven clinical study conducted in China. The primary objective of this study is to determine whether long-term treatment with different doses of colchicine reduces the incidence of cardiovascular events in Chinese patients undergoing PCI. The secondary objective is to determine the safety of long-term treatment with different doses of colchicine in this patient population.

Read the detailed description

After informed consent, 8862 subjects who meet all inclusion will be randomly assigned to receive colchicine (0.5 mg/day), colchicine (0.375 mg/day), or placebo (1:1:1 allocation ratio), with follow-up at months (1, 6, 12, 18, 24…) after randomization, and phone assessments at months (3, 9, 15, 21…). The occurrence of any endpoints or other adverse events will be assessed every 3 months. Subjects will also receive standard medical care for antiplatelets, control of dyslipidemia, hypertension, angina and diabetes as directed by national guidelines. All suspected cardiovascular endpoints will be adjudicated by the Clinical Event Committee (CEC, consisting of three experienced members blinded as to allocation of therapy). The Data and Safety Monitoring Board (DSMB, consisting of five fully independent members) will review unblinded safety data as detailed in the DSMB charter. An interim analysis is planned after approximately 50% of primary endpoints have been positively adjudicated. The DSMB charter will pre-specify the methodology for the interim analysis and the rules for early termination of the study.

03

Conditions studied

  • Coronary Heart Disease
  • Percutaneous Coronary Intervention
  • Colchicine

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (1) Capable and willing to provide ;
  • (2) Age ≥18 and ≤80 years old, regardless of sex;
  • (3) Hospitalized patients with CHD requiring PCI;
  • (4) Completion of all planned PCI during hospitalization;
  • (5) Standardized treatment of coronary artery disease according to national guidelines.

Exclusion criteria

Exclusion Criteria:

  • (1) Known allergy to colchicine;
  • (2) Colchicine taken within 10 days prior to randomization group;
  • (3) Patients currently in cardiogenic shock or hemodynamically unstable;
  • (4) Patients with known inflammatory bowel disease or chronic diarrhea;
  • (5) Abnormal liver function (> 3 times the );
  • (6) Abnormal renal function (\<30mL/min/1.73m2);
  • (7) Active malignant tumors reported in past medical history;
  • (8) Existing or planned treatment with other anti-inflammatory or drugs;
  • (9) Pregnant women, lactating women or women of childbearing age who did not use effective ;
  • (10) Any other circumstances in which the investigator judges that the patient is not suitable to participate in the clinical trial.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
8,862 participants (estimated)

Study arms

  • Experimental
    Colchicine 0.5 mg

    Colchicine 0.5 mg, one pill a day, oral intake

    Drug: Colchicine 0.5 mg

  • Experimental
    Colchicine 0.375 mg

    Colchicine 0.375 mg, one pill a day, oral intake

    Drug: Colchicine 0.375 mg

  • Placebo comparator
    Placebo

    Placebo, one pill a day, oral intake

    Drug: Placebo

Interventions

  • DrugColchicineStudies of ColchicineColchicine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Colchicine 0.5 mg, one pill a day, oral intake

    Also known as: no other name

  • DrugColchicineStudies of ColchicineColchicine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Colchicine 0.375 mg, one pill a day, oral intake

    Also known as: no other name

  • DrugPlacebo

    Placebo, one pill a day, oral intake

    Also known as: no other name

06

What researchers measure

Primary outcomes

  1. Composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and ischemia-driven revascularization

    From randomization to the first occurrence

    Time frame: An estimated 2-4 years period

Secondary outcomes

  1. Composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke

    From randomization to the first occurrence

    Time frame: An estimated 2-4 years period

  2. Ischemia-driven revascularization

    The number of participants with Ischemia-driven revascularization

    Time frame: An estimated 2-4 years period

  3. Nonfatal myocardial infarction

    The number of participants with myocardial infarction

    Time frame: An estimated 2-4 years period

  4. Nonfatal stroke

    The number of participants with stroke

    Time frame: An estimated 2-4 years period

  5. Urgent hospitalization for unstable angina

    The number of participants with urgent hospitalization for unstable angina

    Time frame: An estimated 2-4 years period

  6. In-stent restenosis

    The number of participants with in-stent restenosis

    Time frame: An estimated 2-4 years period

  7. Stent thrombosis

    The number of participants with stent thrombosis

    Time frame: An estimated 2-4 years period

  8. Cardiovascular death

    The number of participants with cardiovascular death

    Time frame: An estimated 2-4 years period

  9. All-cause mortality

    The number of participants with all-cause death

    Time frame: An estimated 2-4 years period

07

Study locations

36 sites
08

References and documents

Publications

  • Lawler PR, Bhatt DL, Godoy LC, Luscher TF, Bonow RO, Verma S, Ridker PM. Targeting cardiovascular inflammation: next steps in clinical translation. Eur Heart J. 2021 Jan 1;42(1):113-131. doi: 10.1093/eurheartj/ehaa099. PubMed 32176778 ↗
  • Nelson K, Fuster V, Ridker PM. Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2023 Aug 15;82(7):648-660. doi: 10.1016/j.jacc.2023.05.055. PubMed 37558377 ↗
  • Fiolet ATL, Opstal TSJ, Mosterd A, Eikelboom JW, Jolly SS, Keech AC, Kelly P, Tong DC, Layland J, Nidorf SM, Thompson PL, Budgeon C, Tijssen JGP, Cornel JH. Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. Eur Heart J. 2021 Jul 21;42(28):2765-2775. doi: 10.1093/eurheartj/ehab115. PubMed 33769515 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2024 (actual). Primary completion is estimated for Jun 2027, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2024
First posted
Jun 25, 2024
StartActual
Jul 9, 2024
Primary completionEst.
Jun 30, 2027
CompletionEst.
Aug 31, 2027
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06472908
Responsible party
Xiang Cheng (Director in the department of cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology) — Principal investigator
First posted
Jun 25, 2024
Start date
Jul 9, 2024
Primary completion
Jun 30, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Sep 3, 2026

Study contacts

Xiang Cheng, MD
principal investigator · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Colchicine

Start the discussion